Does the addition of N-terminal pro–B-type natriuretic peptide measurement to the Canadian Syncope Risk Score improve the prediction of 30-day serious adverse events in emergency department patients presenting with syncope?

BEEM Bottom Line

Why is this study important?

Syncope is a common emergency department (ED) complaint that presents clinicians with the challenge of identifying patients at risk for serious adverse events (SAEs). Cardiac biomarkers such as natriuretic peptides and high-sensitivity troponin have demonstrated some prognostic value in risk stratification of ED patients with syncope.[1] [2] This study evaluated whether adding N-terminal pro–B-type natriuretic peptide (NT-proBNP) to the Canadian Syncope Risk Score (CSRS) improves prediction of 30-day SAEs in ED patients with syncope.

Which, if any, threats to validity are most likely to have an impact on the results and how?

Thank you for your interest in the BEEM Journal!

To read the rest of this article or to access the entire collection of BEEM Critical Appraisals, please purchase a subscription at the link below.

If you would like a pre-view, click here to view some sample articles

Premium Content Available Through Subscription

BEEM is a knowledge translation project which aims to extract the most recent, EM relevant, and valid evidence from the volumes of available medical research and deliver it to EM practitioners in an easily consumable format to help guide their clinical practice. This valuable distilled information provided by BEEM is available through BEEM's accredited CME courses or through our online journal.

A BEEM Journal Subscription will provide you with unlimited access to our entire collection of Critical Appraisals for 1 year.